Thesis
Sonelokimab's BLA submission in HS and Phase 3 PsA readout test whether best-in-class IL-17A/F inhibition translates to regulatory approval and label breadth
Sonelokimab is an IL-17A/F nanobody targeting adults and adolescents with moderate-to-severe hidradenitis suppurativa and active psoriatic arthritis. The thesis resolves on FDA acceptance and approval of the HS BLA combined with a positive IZAR-1 primary endpoint in PsA. Bimekizumab (UCB) and secukinumab (Novartis), both approved in HS, establish a high commercial bar that sonelokimab must clear on efficacy differentiation and market access.
Focus
BLA submission in hidradenitis suppurativa
September 2026
Bull
A clean BLA submission accepted by FDA with Priority Review designation would compress the approval timeline and validate the label strategy — adult plus adolescent (ages 12+) coverage — positioning sonelokimab as the first IL-17A/F inhibitor approved in HS with best-in-class efficacy data (67.2% HiSCR75 at Week 52, ~10 percentage points above comparable IL-17A inhibitors) and a differentiated adolescent label that no competitor currently holds.
Bear
The most likely failure modes are a Refuse-to-File decision if FDA identifies deficiencies in the chemistry, manufacturing, or controls package, or a Complete Response Letter requesting additional data on the proposed label scope — particularly if FDA does not accept the MIRA trial as substantial evidence of effectiveness or limits the label to adults only, stripping the pediatric differentiation that underpins the Priority Review request.
Unlock the full thesis for MLTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.